Vanda Pharmaceuticals Inc. (VNDA) Trading 8.2% Higher

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares traded up 8.2% on Monday . The stock traded as high as $16.00 and last traded at $15.90. 816,108 shares traded hands during trading, an increase of 39% from the average session volume of 587,109 shares. The stock had previously closed at $14.70.

Several research analysts have weighed in on the company. ValuEngine lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Oppenheimer Holdings Inc. set a $21.00 target price on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. HC Wainwright set a $18.00 target price on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a report on Tuesday, October 24th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $22.00.

The company’s 50 day moving average price is $17.04 and its 200 day moving average price is $15.81. The stock’s market cap is $713.24 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.18. The company had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The business’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.01 EPS. Equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post ($0.43) EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd boosted its position in shares of Vanda Pharmaceuticals by 46.3% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 6,487 shares in the last quarter. Birchview Capital LP boosted its position in shares of Vanda Pharmaceuticals by 25.9% during the 2nd quarter. Birchview Capital LP now owns 68,000 shares of the biopharmaceutical company’s stock worth $1,108,000 after purchasing an additional 14,000 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $538,000. American International Group Inc. boosted its position in shares of Vanda Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 1,491 shares in the last quarter. Finally, AJO LP boosted its position in shares of Vanda Pharmaceuticals by 94.2% during the 2nd quarter. AJO LP now owns 541,927 shares of the biopharmaceutical company’s stock worth $8,833,000 after purchasing an additional 262,833 shares in the last quarter. 86.52% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) Trading 8.2% Higher” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/10/30/vanda-pharmaceuticals-inc-vnda-trading-8-2-higher.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

What are top analysts saying about Vanda Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vanda Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit